Minimally invasive diagnostic and prognostic blood tests
Avoiding unnecessary biopsies is a key focus for Biosignatures. The company's first product BiopSave, has passed its first independent clinical trial. Two other products in bladder and renal cancers are in early development.
This test was developed to tackle the major clinical issue of the large number of unnecessary biopsies used during the current diagnosis process for prostate cancer. In 2016, the product demonstrated it was 4X more effective than PSA and 56% better than the leading competitor in an independently blinded clinical validation trial.
This test augments the current bladder cancer diagnostic processes and helps reduce the number of invasive and expensive cystoscopy examinations which are performed. It has successfully completed an initial blinded validation trial.
This test was developed to identify renal cancer without exploratory surgery which is currently required. It has successfully completed an initial blinded validation trial.
Feel free to get in touch about any aspect of Biosignatures and our range of products.